Molecular basis of AmpC hyperproduction in clinical isolates of Escherichia coli.
DNA sequencing data showed that five clinical isolates of Escherichia coli with reduced susceptibility to ceftazidime, ceftriaxone, and cefotaxime contain an ampC gene that is preceded by a strong promoter. Transcription from the strong promoter was 8- to 18-fold higher than that from the promoter from a susceptible isolate. RNA studies showed that mRNA stability does not play a role in the control of AmpC synthesis.
Nelson
E C
EC
Department of Medical Microbiology, University of Cape Town, South Africa.
Elisha
B G
BG
D001483:Base Sequence; D002442:Ceftazidime / Q000494:pharmacology; D018550:Cephalosporin Resistance / Q000235:genetics*; D004926:Escherichia coli / Q000235:genetics*; D015964:Gene Expression Regulation, Bacterial; D005798:Genes, Bacterial / Q000235:genetics* / Q000502:physiology; D006801:Humans; D008969:Molecular Sequence Data; D009692:Nucleic Acid Heteroduplexes; D012333:RNA, Messenger / Q000378:metabolism; D012045:Regulatory Sequences, Nucleic Acid / Q000235:genetics; D017422:Sequence Analysis, DNA; D012689:Sequence Homology, Nucleic Acid
D009692:Nucleic Acid Heteroduplexes; D012333:RNA, Messenger; D002442:Ceftazidime